Skip to content

A Clinical Trial of Thai Herbal Medicine as Post-exposure Prophylaxis for COVID-19: A pilot study

A Clinical Trial of Thai Herbal Medicine as Post-exposure Prophylaxis for COVID-19: A pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000048
Enrollment
Unknown
Registered
2024-04-21
Start date
2022-01-06
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Treatment :AYW-KK-04 herbal capsule 4 g twice a day
Control :Placebo capsule 4 g twice a day

Sponsors

Suppachai Tiyaworanant and all other members of the research group
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 68 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18 years and over. 2. The individual must have been in close contact with a patient confirmed to have COVID-19 (referred to as the reference patient) for no more than 7 days 3. While in close contact with a with a patient confirmed to have COVID-19 and did not wear a mask. (High risk) with one of the following characteristics 3.1 Provide close care to reference patients 3.2 Physical close contact with reference patients 3.3 Living with the reference patient 3.4 Sitting with a reference patient in an enclosed space, at a distance of no more than 2 meters, with or without direct contact for at least 1 hour. 3.5 Direct contact with body secretions of reference patients, such as mucus, saliva, tears, urine, and feces. 4. Have complete awareness and be able to know, understand and make decisions.

Exclusion criteria

Exclusion criteria: 1. was diagnosed and required hospital treatment 2. Tested with RT-PCR and confirmed to be infected with COVID-19. 3. Have a history of allergic reaction to herbs that are ingredients in the recipe 4. Have a history of allergic reaction to the proteins that make up the capsules 5. Are pregnant or have had a positive pregnancy test result 6. Having complete blood count, liver and kidney function that is abnormal from the standard values that the hospital considers or according to the doctor's opinion that such values are abnormal cannot be entered into the research process. 7. Intend to use other herbal medicines for treatment such as Andrographis paniculata and Krachai.

Design outcomes

Primary

MeasureTime frame
The primary outcome of this clinical trial is the COVID-19 polymerase chain reaction (PCR) test result of research participants.;

Countries

Thailand

Contacts

Public ContactSuppachai Tiyaworanant

Khon Kaen University

suptiy@kku.ac.th+66885630564

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026